[Value of FOXP3 Tregs predicting the effectiveness of neoadjuvant chemotherapy in patients with breast cancer].
OBJECTIVE
To explore the predictive significance of FOXP3 Tregs in patients with breast cancer on neoadjuvant chemotherapy (NACT).


METHODS
A total of 78 newly diagnosed and untreated patients with invasive breast cancer were recruited for this retrospective study.FOXP3 Tregs were assessed by immunohistochemistry. The relationship between clinicopathological factors, FOXP3+ Tregs and pathological complete response (pCR) rate was analyzed.


RESULTS
Among 78 patients with TAC neoadjuvant chemotherapy, the pCR rate was 19.2%. The pCR rate of patients with high expressions of FOXP3+ Tregs was significantly lower than that of those with low expressions of FOXP3+ Tregs (9.5% vs 30.5%, P = 0.023). FOXP3+ Tregs expression in breast cancer and efficacy of NACT were negatively correlated.


CONCLUSIONS
FOXP3+ Tregs may serve as a predictor for assessing the efficacy of NACT.
Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China. Email: susujing126@126.com.
Jing
J
Su
Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Hanghang
H
Chen
Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Mengquan
M
Li
Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Jiahan
J
Dong
Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Zhiwei
Z
Lin
D001943:Breast Neoplasms; D051858:Forkhead Transcription Factors; D006801:Humans; D007150:Immunohistochemistry; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D012189:Retrospective Studies; D050378:T-Lymphocytes, Regulatory
C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors